Pfizer Inc. company was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. (Pfizer) is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals. In June 2008, Pfizer completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals, Inc. through a merger of Pfizer's wholly owned subsidiary, Explorer Acquisition Corp., with and into Encysive. In July 2009, Pfizer bought back a 29.52% stake in its Indian arm, Pfizer Limited, increasing its stake to 70.75%.In October 2009, Pfizer Inc. acquired Wyeth. In December 2009, Durata Therapeutics, Inc. acquired Vicuron Pharmaceuticals from Pfizer.
Ortho-McNeil, a subsidiary of gigantic healthcare company Johnson & Johnson, makes a variety of women's health and contraceptive products. A division of Ortho-McNeil-Janssen Pharmaceuticals, its women's health line is dominated by oral contraceptives, including Ortho-cyclen, Ortho-novum, and Modicon; other products include Ditropan for overactive bladder treatment and yeast infection drug Terazol. Sister company Ortho-McNeil Neurologics was created to hold Ortho-McNeil's central nervous system drugs, including epilepsy treatment Topamax, pain management drug Ultracet, Alzheimer's treatments, and migraine remedies, allowing the company to focus strictly on women's health.
Neos Therapeutics makes generic drugs take their time. The contract pharmaceutical manufacturer develops and manufactures branded and generic prescription and OTC pharmaceuticals with an emphasis on time-released formulations. Its products include cold and cough remedies and nutritional supplements. Customers are primarily pharmaceutical distributors and other manufacturers. Neos Therapeutics was slapped hard by the FDA in 2007 for manufacturing unapproved drugs. The action prompted a change in ownership and the company was required to re-file its drug applications in order to resume manufacturing.
AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.
Gentronix is a biotechnology company that provides pharmaceutical makers with drug development products and monitoring services. Gentronix's products and services are geared toward helping drug discovery scientists speed up pre-clinical research and development. The company's main product, Greenscreen, uses cellular biosensor technology to test potential pharmaceutical compounds for genotoxicity (DNA damage) and cytotoxicity (general cellular damage). The company was founded in 1999 as part of the University of Manchester Institute of Science and Technology's Biomolecular Sciences and Instrumentation & Analytical Science departments.
Gentium S.p.A was founded in 1993 and is based in Villa Guardia, Italy. Gentium S.p.A., a biopharmaceutical company, engages in the research, development, and manufacture of drugs to treat and prevent various vascular diseases and conditions related to cancer and cancer treatments. It develops and manufactures defibrotide, DNA based drug derived from pig intestines, to treat and prevent hepatic veno-occlusive disease (VOD), a condition in which some of the veins in the liver are blocked as a result of cancer treatments, such as chemotherapy prior to stem cell transplantation. The company conducts a phase III clinical trial of defibrotide to treat severe VOD in the United States, Canada, and Israel. It also conducts a phase II/III clinical trial of defibrotide in Europe to prevent VOD in children. In addition, the company offers Sulglicotide that is developed from swine duodenum and has ulcer healing and gastrointestinal protective properties; and Urokinase to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms.
Merck OY company, a subsidiary of Germany-based Merck KGaA, manufactures, markets, and distributes prescription and over-the-counter pharmaceutical medicines. Merck OY's prescription drugs fall into targeted therapeutic categories such as diabetes, cardiovascular care, and infertility, and its consumer health care segment primarily consists of nutraceutical (vitamin) products. It also makes select chemical products, including liquid crystals and life science laboratory chemicals.
Genmab was founded in 1999. Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to treat such conditions as lymphoma and other cancers, as well as autoimmune and inflammatory diseases. It has assembled a portfolio of products under its HuMax brand that are in different stages of development, ranging from pre-clinical to late-stage trials. In addition to developing its HuMax products, Genmab is working to create products for conditions such as infectious diseases and vascular conditions. The company has licensing and development partnerships with several international pharmaceutical and biotech companies including GlaxoSmithKline, Amgen, Medarex, and Roche.
The revolution in genomics and proteomics spawned by the human genome project is providing a steady stream of protein therapeutic candidates. Many of these proteins require enhancements in their pharmacokinetic properties in order to be clinically effective because of inherent limitations of proteins as drugs. Advanced Proteome Therapeutics has initiated a program that is broadly applicable to proteins. It builds on a technology platform developed over twenty years of targeting proteins for site-selective modification and addresses issues which limit therapeutic utilization of promising proteins.The Company’s laboratories are located at the BioSquare Innovation and Discovery Center on the campus of the Boston University School of Medicine. Its scientists are engaged in research and development applying leading edge chemical and biochemical methodologies to commercially viable proteins. The technology is applicable to the generation of a variety of protein products including protein therapeutics, protein diagnostics and high value reagents for research.
Obagi Medical Products, Inc. company was founded in 1988 and is headquartered in Long Beach, California. Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.